Please assess the completion status of the following clinical trial:

Trial Title: Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II grade~* Undergoing elective video-assisted pneumonectomy under general anesthesia.~* Participants aged from 30-70 years old.~Exclusion Criteria:~* Refusal for paravertebral block~* Inability to obtain informed consent~* Coagulation disorders, neuropathy, or body mass index greater than 40 kg/m2~* Pregnancy~* Infections at the site of injection for the paravertebral block~* Allergy to local anesthetics or alpha-2 adrenergic agonists~* Heart block or bradycardia (heart rate \< 60 beat per minute)~* Clinically significant cardiovascular, pulmonary, renal, or hepatic diseases

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine and dexmedetomidine (Type: EXPERIMENTAL): Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
- Ropivacaine only (Type: ACTIVE_COMPARATOR): Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).